|
2025
|
Invention
|
Jak1 pathway inhibitors for the treatment of prurigo nodularis.
This disclosure relates to JAK1 ... |
|
|
Invention
|
Heterocyclic compounds as immunomodulators.
Disclosed are compounds of Formula (I′), methods of ... |
|
|
Invention
|
1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet pr... |
|
2024
|
Invention
|
Bicyclooctane kras inhibitors.
Disclosed are compounds of Formula (I), methods of using the comp... |
|
|
Invention
|
Bicyclooctane kras inhibitors. Disclosed are compounds of Formula (I), methods of using the compo... |
|
|
Invention
|
Ruxolitinib for the treatment of prurigo nodularis.
This disclosure relates to ruxolitinib, or a... |
|
|
Invention
|
Combination therapy comprising dgk inhibitors and pd-1/pd-l1 inhibitors.
The present application... |
|
|
Invention
|
Combination therapy comprising dgk inhibitors and pd-1/pd-l1 inhibitors. The present application ... |
|
|
Invention
|
Tricyclic triazolo compounds as dgk inhibitors. The present application provides tricyclic triazo... |
|
|
Invention
|
Tricyclic triazolo compounds as dgk inhibitors.
The present application provides tricyclic triaz... |
|
|
Invention
|
Combinations and uses thereof.
The present disclosure describes a pharmaceutical combination of ... |
|
|
Invention
|
Ruxolitinib for treating hidradenitis suppurativa (hs). This disclosure relates to methods for tr... |
|
|
Invention
|
Salts of tam inhibitors.
The present application provides salt forms of N-(4-(4-Amino-7-(1-isobu... |
|
|
Invention
|
Heterocyclic compounds as immunomodulators.
Disclosed are compounds of Formula (I), methods of u... |
|
|
Invention
|
Heterocyclic kinase inhibitors.
The present application provides naphthyridine and pyridopyridaz... |
|
|
Invention
|
Bicyclic heterocycles as mrgprx2 antagonists.
The present disclosure relates to bicyclic heteroc... |
|
|
Invention
|
Sustained-release dosage forms of ruxolitinib.
The present invention relates to sustained-releas... |
|
|
Invention
|
Kras inhibitors.
Disclosed are compounds of Formula (I), methods of using the compounds for inhi... |
|
|
Invention
|
Anti-mutant calreticulin (calr) antibody-drug conjugates and uses thereof. Anti-mutant calreticul... |
|
|
Invention
|
Kras inhibitors. Disclosed are compounds of Formula (I), methods of using the compounds for inhib... |
|
|
Invention
|
Ruxolitinib for use in the treatment of prurigo nodularis. This disclosure relates to ruxolitinib... |
|
|
Invention
|
Crystalline forms of 3-(1-(( 1 r,4r,5s)-2-azabicyclo[2.1.1 ]hexan-5-yl)-2-(( 1 r,3r,5r)-2-( cyclo... |
|
|
Invention
|
Processes for preparing kras inhibitors. This disclosure provides efficient and scalable processe... |
|
|
Invention
|
Combination comprising a kras g12d inhibitor and an egfr inhibitor for use in the treatment of ca... |
|
|
Invention
|
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor. Provided h... |
|
|
Invention
|
Crystalline forms of a kras inhibitor.
This disclosure provides salts, crystalline forms, and fo... |
|
|
Invention
|
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor.
Provided ... |
|
|
Invention
|
Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor.
Provided herein are ... |
|
|
Invention
|
Spirocyclic lactam inhibitors.
The present application provides bicyclic spriolactam compounds t... |
|
|
Invention
|
Kinase inhibitors and degraders.
The present application provides heterocyclic compounds that mo... |
|
|
Invention
|
Kinase inhibitors.
The present application provides heterocyclic compounds that modulate the act... |
|
|
Invention
|
Combination therapy with an anti-cd19 antibody and parsaclisib.
The present disclosure describes... |
|
|
Invention
|
Bicyclic dgk inhibitors.
The present application provides bicyclic compounds that modulate the a... |
|
|
Invention
|
6-((4-(bis(phenyl)methyl)-2,5-piperazin-1-yl)-9-(tetrahydrofuran-2-yl)methyl)-3,9-dihydro-2h-puri... |
|
|
Invention
|
Bicyclic heterocycles as mrgprx2 antagonists. The present disclosure relates to bicyclic heterocy... |
|
|
Invention
|
Tricyclic urea compounds as jak2 v617f inhibitors.
The present application provides tricyclic ur... |
|
|
Invention
|
Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 r... |
|
|
Invention
|
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment.
The present d... |
|
|
Invention
|
Bicyclic heterocycles as fgfr inhibitors.
The present invention relates to bicyclic heterocycles... |
|
|
Invention
|
Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma.
Th... |
|
|
Invention
|
Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy.
Disclosed are combi... |
|
|
Invention
|
Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors.
The present application provid... |
|
|
Invention
|
Triazolopyrimidines as a2a / a2b inhibitors.
This application relates to compounds of Formula (I... |
|
|
Invention
|
Tricyclic compounds as inhibitors of kras.
Disclosed are compounds of Formula I, methods of usin... |
|
|
Invention
|
Salts of an fgfr inhibitor.
The present invention relates to salt forms of the Fibroblast Growth... |
|
|
Invention
|
Jak inhibitor with a vitamin d analog for treatment of skin diseases.
The present disclosure rel... |
|
|
Invention
|
Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active age... |
|
2010
|
P/S
|
Pharmaceutical preparations for use in the treatment of oncological, hematological and inflammato... |
